Trial Profile
Thorough QT (TQT) clinical trial evaluating the effects of deutetrabenazine (SD 809) on cardiac repolarisation in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary) ; Moxifloxacin; Tetrabenazine
- Indications Chorea
- Focus Adverse reactions
- Sponsors Auspex Pharmaceuticals
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 20 Jan 2015 New trial record